The COVID-19 pandemic demonstrated that the mass production of vaccines is crucial for our healthcare system. In order to provide large quantities in a short time span, high capacity technology is inevitable2,3. IDT Biologika has established a pandemic preparedness concept that demonstrates our readiness for viral vector vaccine mass production. In this manner, we have developed an exemplary process for Adenovirus (AdV) vector manufacturing and successfully scaled it up into a 2000 L stirred tank reactor (STR). Here we describe our work flow and the challenges that we overcame during the process development.